What Is Kisspeptin?

Overview

Kisspeptin refers to a family of neuropeptides derived from the KISS1 gene, originally discovered in 1996 by Danny R. Welch and J.H. Lee in Hershey, Pennsylvania, as a melanoma metastasis suppressor. The gene was named "KiSS-1" to honor the discovery location near the Hershey's Kisses chocolate factory, with "SS" denoting "suppressor sequence."[1]

The KISS1 gene encodes a 145-amino acid prepro-kisspeptin precursor that undergoes proteolytic cleavage to produce four biologically active isoforms: Kisspeptin-54 (Kp-54), Kp-14, Kp-13, and Kp-10. All isoforms share a conserved C-terminal decapeptide containing an RF-amide motif (Arg-Phe-NH₂) essential for binding and activating the KISS1R (GPR54) receptor.[2][3]

Kp-54 is the major circulating form with a half-life of ~27.6 minutes; the shorter Kp-10 (~4 min half-life) exhibits full intrinsic bioactivity and is highly conserved across species.[5]

In 2003, Stephanie Seminara and colleagues made the landmark discovery that loss-of-function mutations in KISS1R (GPR54) cause idiopathic hypogonadotropic hypogonadism and pubertal failure — establishing kisspeptin as the gatekeeper of sexual maturation.[4]

Kisspeptin is currently investigational — not approved by the FDA or EMA for general clinical use. It is prohibited by WADA under S2 (Peptide Hormones, Growth Factors) as it stimulates LH/FSH/testosterone production.[7]

Discovery and design rationale

Kisspeptin was originally identified as a metastasis-suppressor gene product before its role as a master HPG-axis regulator was uncovered. Subsequent investigations dissected the precursor into Kp-54, Kp-14, Kp-13, and Kp-10 isoforms and established that the C-terminal RF-amide decapeptide retained full intrinsic bioactivity. Synthetic analogs MVT-602 and TAK-448 were engineered with metalloprotease-resistant backbones to extend the in-vivo signature beyond the brief plasma half-life of native Kp-10, producing research tools suitable for pulse, continuous-infusion, and once-weekly experimental paradigms. [9]

Research framework

Within the reproductive and neuroendocrine peptide research family, kisspeptin is most directly compared with oxytocin (nonapeptide investigated for parallel social/limbic-bonding endpoints), the GnRH-axis tool family represented by sermorelin and tesamorelin (GHRH analogs that interrogate adjacent hypothalamic releasing-hormone systems), and Melanotan-II (melanocortin-receptor agonist used in limbic-processing research). These cross-comparisons inform research interrogating how a single hypothalamic gatekeeper interacts with neighbouring HPG, HPA, and melanocortin networks. [3]